MAX
MAX (MYC associated transcriptional regulator X) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Neuroendocrine tumours, Multiple myeloma, Endometrial cancer and 5 more.
Overview
Transcription regulator. Forms a sequence-specific DNA-binding protein complex with MYC or MAD which recognises the core sequence 5'-CAC[GA]TG-3'. The MYC:MAX complex is a transcriptional activator, whereas the MAD:MAX complex is a repressor.
Open Targets scores its association with cancer at 0.74 (direct and indirect evidence; datatypes literature 0.89, genetic association 0.17, somatic mutation 0.95). IntOGen calls it a driver in 10 cohorts (7 activating, 3 loss-of-function), covering Invasive Breast Carcinoma, Gastrointestinal Stromal Tumour, Low-Grade Glioma, NOS, Medulloblastoma, Pilocytic Astrocytoma, Plasma Cell Myeloma and others.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · MAX (MYC associated transcriptional regulator X) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Neuroendocrine tumours, Multiple myeloma, Endometrial cancer and 5 more.
- 1 · What it is
MAX (MYC associated transcriptional regulator X) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Neuroendocrine tumours, Multiple myeloma, Endometrial cancer and 5 more.
- 2 · What goes wrong in cancer
Transcription regulator. Forms a sequence-specific DNA-binding protein complex with MYC or MAD which recognises the core sequence 5'-CAC[GA]TG-3'.
- 3 · How drugs use it
No product in this corpus aims at MAX yet. Transcription factors have no pocket to plug, so drugs either degrade them or block the partner protein they need to dock on DNA.
External identifiers
Sources: HGNC HGNC:6913 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P61244 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000125952 (association with cancer (MONDO_0004992) 0.74; per-cancer scores at or above 0.5: colorectal cancer 0.53, melanoma 0.52, neuroendocrine neoplasm 0.76, plasma cell myeloma 0.51, skin cancer 0.53, breast cancer 0.55 (GraphQL API, CC0)); IntOGen MAX (driver in 10 cohorts (Act 7, LoF 3); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Biology
Transcription regulator. Forms a sequence-specific DNA-binding protein complex with MYC or MAD which recognises the core sequence 5'-CAC[GA]TG-3'. The MYC:MAX complex is a transcriptional activator, whereas the MAD:MAX complex is a repressor. May repress transcription via the recruitment of a chromatin remodeling complex containing H3 'Lys-9' histone methyltransferase activity. Represses MYC transcriptional activity from E-box elements. Location: Nucleus; Cell projection, dendrite (UniProt). Locus 14q23.3 (HGNC).
- Neuroendocrine tumours: Open Targets association 0.76 with neuroendocrine neoplasm (MONDO_0019496)
- Multiple myeloma: Open Targets association 0.51 with plasma cell myeloma (MONDO_0009693); IntOGen driver in 2 cohorts (PCM)
- Endometrial cancer: IntOGen driver in 2 cohorts (UCEC)
- Breast cancer: Open Targets association 0.55 with breast cancer (MONDO_0007254); IntOGen driver in 1 cohort (BRCA)
- Small intestine cancer: IntOGen driver in 1 cohort (SIC)
- Colorectal cancer: Open Targets association 0.53 with colorectal cancer (MONDO_0005575)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it an activating (Act) driver in 7 cohorts; IntOGen calls it a loss-of-function (LoF) driver in 3 cohorts. Evidence tier "cohort-driver" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
- Diseases the sources name that have no OnCo cancer page yet, so they are not linked: Low-Grade Glioma, NOS.
Latest papers
topQuery for this target: (TITLE:"MAX" OR ABSTRACT:"MAX" OR TITLE:"MYC associated transcriptional regulator X" OR ABSTRACT:"MYC associated transcriptional regulator X" OR TITLE:"bHLHd4" OR ABSTRACT:"bHLHd4" OR TITLE:"bHLHd5" OR ABSTRACT:"bHLHd5" OR TITLE:"bHLHd6" OR ABSTRACT:"bHLHd6" OR TITLE:"bHLHd7" OR ABSTRACT:"bHLHd7") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about MAX, not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetSDHC
Shares Gastrointestinal stromal tumour (GIST), Neuroendocrine tumours, Breast cancer (all types), Open Targets Platform.
- TargetCDKN1B
Shares Small intestine cancer (small bowel adenocarcinoma), Neuroendocrine tumours, Breast cancer (all types), IntOGen.
- TargetSDHB
Shares Gastrointestinal stromal tumour (GIST), Neuroendocrine tumours, Breast cancer (all types), Open Targets Platform.
- TargetSDHA
Shares Gastrointestinal stromal tumour (GIST), Neuroendocrine tumours, IntOGen, Open Targets Platform.
- TargetSNX29
Shares Small intestine cancer (small bowel adenocarcinoma), IntOGen.
- JournalJournal of gastrointestinal cancer
Shares Small intestine cancer (small bowel adenocarcinoma), Gastrointestinal stromal tumour (GIST), Colorectal cancer.
- TargetPTPRD
Shares Small intestine cancer (small bowel adenocarcinoma), Breast cancer (all types), IntOGen.
- TargetNUP214
Shares Small intestine cancer (small bowel adenocarcinoma), IntOGen, Open Targets Platform.